Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 WindMIL Therapeutics Announces Key Appointment | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

WindMIL Therapeutics Announces Key Appointment

Dr. Sanjin Zvonić joins the company with over 15 years experience to prepare him for the role of vice president of Process Science and Manufacturing

By: Betsy Louda

, Contract Pharma

WindMIL Therapeutics has announced the appointment of Sanjin Zvonić, PhD, as vice president of Process Science and Manufacturing. 

 
In this role, Dr. Zvonić will oversee manufacturing for all of WindMIL’s cell therapies, ensuring the company supplies product to meet the demands of several upcoming clinical studies, and ultimately, position WindMIL therapeutic candidates for commercialization.
 
“Sanjin brings to WindMIL more than 15 years of experience in the development and manufacturing of cell-based therapeutics, with an impressive scientific and technical background in physiology, stem cell biology, and cell therapy CMC development. At WindMIL, we’re always looking to the future of cancer immunotherapy, so Sanjin’s ability to bridge research and manufacturing makes him an ideal fit for us as we deliver both the current generation of MILs™ and look toward developing the next generation,” said Don Hayden, Interim chief executive officer and executive chairman of WindMIL Therapeutics. “We are also fortunate that Sanjin is very focused on people development. Having him join WindMIL during this time of growth will help ensure we develop the team to its greatest potential.”

Prior to joining WindMIL, Dr. Zvonić served as senior director and Business Leader of Clinical and Commercial Manufacturing at Hitachi Chemical Advanced Therapeutics Solutions (HCATS), LLC, as Progenitor Cell Therapy (PCT) integrated into Hitachi. 
“I’m honored to join the WindMIL team as we continue to grow and find new ways to translate novel insights in bone marrow immunology into our MILs™ technology platform, creating life-saving cell therapies for cancer patients,” said Dr. Zvonić. “It’s an exciting time to join such a ground-breaking company.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics